Skip to main content
Top

27-08-2016 | Hepatocellular carcinoma | Article

1. Epidemiology of Hepatocellular Carcinoma

Authors: Donna L. White, Fasiha Kanwal, Li Jiao, Hashem B. El-Serag

Publisher: Springer International Publishing

Abstract

Liver cancer is the second leading cause of cancer-related mortality resulting in 745,000 deaths annually worldwide. It is overwhelmingly manifest as hepatocellular carcinoma (HCC) arising in middle-aged and older adults. It is also largely a preventable disease. Globally, most cases are related to chronic hepatitis B virus (HBV) infection, and occur in sub-Saharan Africa and Eastern Asia (except Japan). In contrast, hepatitis C virus (HCV) is the leading cause in North America and Western Europe. Recent rapid increases in HCC rates have been observed in several Western populations (particularly in the U.S.) and largely parallel rapidly increasing rates of obesity and diabetes. Striking geographic and racial variations in HCC risk are also evident and likely predominantly due to known differences in the prevalence of major risk factors like HBV and HCV infections. Other established risk factors for HCC include older age, male sex, heavy alcohol intake, aflatoxin exposure, iron overload related to hemochromatosis, and possibly tobacco smoking. The role of diet is largely unknown; however, higher levels of caffeinated coffee consumption are consistently associated with decreased HCC risk across diverse viral and nonviral disease etiologies and populations. Host inherited genetic variation is also being increasingly examined in association with HCC risk, but definitive data are largely lacking. Overall, most HCC risk factors operate by promoting the development of cirrhosis which is primary precursor lesion in most cases. Once cirrhosis is established, the annual risk of HCC ranges between 1 and 7 % thereafter, with particularly increased risk of progression in males with chronic HCV infection. This review discusses in detail the epidemiology of liver cancer, and particularly of HCC, from a global perspective.
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012: cancer incidence and mortality, version 1.1. IARC Cancer Base ed. Lyon: IARC; 2014.
2.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.PubMedCrossRef
3.
McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. Int J Cancer. 2001;94(2):290–6.PubMedCrossRef
4.
Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol. 2002;17(10):1049–55.PubMedCrossRef
5.
Sithithaworn P, Yongvanit P, Duenngai K, Kiatsopit N, Pairojkul C. Roles of liver fluke infection as risk factor for cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2014;21(5):301–8.PubMedCrossRef
6.
Kamsa-Ard S, Wiangnon S, Suwanrungruang K, Promthet S, Khuntikeo N, Kamsa-Ard S, et al. Trends in liver cancer incidence between 1985 and 2009, Khon Kaen, Thailand: cholangiocarcinoma. Asian Pac J Cancer Prev. 2011;12(9):2209–13.PubMed
7.
Furst T, Duthaler U, Sripa B, Utzinger J, Keiser J. Trematode infections: liver and lung flukes. Infect Dis Clin North Am. 2012;26(2):399–419.PubMedCrossRef
8.
Keiser J, Utzinger J. Food-borne trematodiases. Clin Microbiol Rev. 2009;22(3):466–83.PubMedPubMedCentralCrossRef
9.
Furst T, Keiser J, Utzinger J. Global burden of human food-borne trematodiasis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(3):210–21.PubMedCrossRef
10.
Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336(26):1855–9.PubMedCrossRef
11.
Wen WH, Chen HL, Ni YH, Hsu HY, Kao JH, Hu FC, et al. Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology. 2011;53(2):429–36.PubMedCrossRef
12.
Chen JG, Egner PA, Ng D, Jacobson LP, Munoz A, Zhu YR, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila). 2013;6(10):1038–45.CrossRef
13.
Yu SZ. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol. 1995;10(6):674–82.PubMedCrossRef
14.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.PubMedCrossRef
15.
United States Department of Health and Human Services CfDCaPaNCI. United States Cancer Statistics: 1999–2012. 2015.
16.
IARC. Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1–440.
17.
IARC, Forman D, Bray F, Brewster DH, Gombe MC, Kohler B, Pinerson M et al. Cancer incidence in five continentsm, vol. X (electronic version). 2013. Lyon: International Agency for Research on Cancer.
18.
Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47(Suppl):S2–6.PubMedPubMedCentralCrossRef
19.
Scobie B, Woodfield DG, Fong R. Familial hepatocellular carcinoma and hepatitis B antigenemia in a New Zealand Chinese family. Aust N Z J Med. 1983;13(3):236–9.PubMedCrossRef
20.
Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, et al. Family history of liver cancer and hepatocellular carcinoma. Hepatology. 2012;55(5):1416–25.PubMedCrossRef
21.
Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109(4):542–53.PubMedPubMedCentralCrossRef
22.
Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140(4):1182–8.PubMedCrossRef
23.
White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10(12):1342–59.PubMedPubMedCentralCrossRef
24.
National Cancer Institute Surveillance EaERSP. SEER Stat Fact Sheets: Liver and Intrahepatic Bile Duct Cancer. 2015.
25.
World Health Organization. Hepatitis: frequently asked questions. 2015.
26.
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385(9963):117–171.
27.
World Health Organization. Hepatitis B: Fact sheet No.204. 2015.
28.
Thiele M, Gluud LL, Fialla AD, Dahl EK, Krag A. Large variations in risk of hepatocellular carcinoma and mortality in treatment naive hepatitis B patients: systematic review with meta-analyses. PLoS ONE. 2014;9(9):e107177.PubMedPubMedCentralCrossRef
29.
Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol. 2002;40(4):1207–9.PubMedPubMedCentralCrossRef
30.
Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001;34(4):593–602.PubMedCrossRef
31.
Ebert G, Allison C, Preston S, Cooney J, Toe JG, Stutz MD, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc Natl Acad Sci U S A. 2015;112(18):5803–8.PubMedPubMedCentralCrossRef
32.
Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2(8):479–86.PubMedCrossRef
33.
Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012;32(2):231–40.PubMedCrossRef
34.
Black AP, Nouanthong P, Nanthavong N, Souvannaso C, Vilivong K, Jutavijittum P, et al. Hepatitis B virus in the Lao People’s Democratic Republic: a cross sectional serosurvey in different cohorts. BMC Infect Dis. 2014;14:457.PubMedPubMedCentralCrossRef
35.
Mohd HK, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42.CrossRef
36.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87.PubMedCrossRef
37.
Global Health Observatory Data Repository 2015.
38.
Benova L, Awad SF, Miller FD, Abu-Raddad LJ. Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt. Hepatology. 2015;61(3):834–42.PubMedCentralCrossRefPubMed
39.
Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology. 2002;62(Suppl 1):8–17.PubMedCrossRef
40.
Taura N, Fukushima N, Yastuhashi H, Takami Y, Seike M, Watanabe H, et al. The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Med Sci Monit. 2011;17(2):H7–11.CrossRef
41.
Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31(3):777–82.PubMedCrossRef
42.
Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138(2):513–21, 521.
43.
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–32.PubMedCrossRef
44.
Freeman AJ, Dore GJ, Law MG, Thorpe M, Von OJ, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34(4 Pt 1):809–16.PubMedCrossRef
45.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73.PubMedPubMedCentralCrossRef
46.
Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831–7.PubMedCrossRef
47.
Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014;60(1):98–105.
48.
El-Serag HB, Kramer J, Duan Z, Kanwal F. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014;109(9):1427–35.PubMedCrossRef
49.
Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108(8):1314–21.PubMedPubMedCentralCrossRef
50.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Alcohol consumption and ethyl carbamate. IARC Monogr Eval Carcinogenic Risks Hum 2010; 96:3–1383.
51.
Li WQ, Park Y, McGlynn KA, Hollenbeck AR, Taylor PR, Goldstein AM, et al. Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study. Hepatology. 2014;60(2):588–97.PubMedPubMedCentralCrossRef
52.
Adami HO, McLaughlin JK, Hsing AW, Wolk A, Ekbom A, Holmberg L, et al. Alcoholism and cancer risk: a population-based cohort study. Cancer Causes Control. 1992;3(5):419–25.PubMedCrossRef
53.
Loomba R, Yang HI, Su J, Brenner D, Iloeje U, Chen CJ. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol 2010;8(10):891–8.
54.
World Health Organization. Global status report on alcohol and health 2014. 2015.
55.
Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350(6317):429–31.PubMedCrossRef
56.
Lai H, Mo X, Yang Y, He K, Xiao J, Liu C, et al. Association between aflatoxin B1 occupational airway exposure and risk of hepatocellular carcinoma: a case-control study. Tumour Biol. 2014;35(10):9577–84.PubMedPubMedCentralCrossRef
57.
Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China. Cancer Epidemiol Biomarkers Prev. 1994;3(1):3–10.PubMed
58.
Yard EE, Daniel JH, Lewis LS, Rybak ME, Paliakov EM, Kim AA, et al. Human aflatoxin exposure in Kenya, 2007: a cross-sectional study. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(7):1322–31.PubMedPubMedCentralCrossRef
59.
Asim M, Sarma MP, Thayumanavan L, Kar P. Role of aflatoxin B1 as a risk for primary liver cancer in north Indian population. Clin Biochem. 2011;44(14–15):1235–40.PubMedCrossRef
60.
Yu MW, Lien JP, Chiu YH, Santella RM, Liaw YF, Chen CJ. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J Hepatol. 1997;27(2):320–30.PubMedCrossRef
61.
Yu MW, Lien JP, Liaw YF, Chen CJ. Effects of multiple risk factors for hepatocellular carcinoma on formation of aflatoxin B1-DNA adducts. Cancer Epidemiol Biomarkers Prev. 1996;5(8):613–9.PubMed
62.
Chen JG, Kensler TW. Changing rates for liver and lung cancers in Qidong. China. Chem Res Toxicol. 2014;27(1):3–6.PubMedCrossRef
63.
Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, et al. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev. 2009;18(3):846–53.PubMedPubMedCentralCrossRef
64.
Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer. 2012;48(14):2125–36.PubMedPubMedCentralCrossRef
65.
Shirima CP, Kimanya ME, Kinabo JL, Routledge MN, Srey C, Wild CP, et al. Dietary exposure to aflatoxin and fumonisin among Tanzanian children as determined using biomarkers of exposure. Mol Nutr Food Res. 2013;57(10):1874–81.PubMedPubMedCentral
66.
Gong YY, Wilson S, Mwatha JK, Routledge MN, Castelino JM, Zhao B, et al. Aflatoxin exposure may contribute to chronic hepatomegaly in Kenyan school children. Environ Health Perspect. 2012;120(6):893–6.PubMedPubMedCentralCrossRef
67.
Matumba L, Van PC, Ediage EN, De SS. Keeping mycotoxins away from the food: does the existence of regulations have any impact in Africa? Crit Rev Food Sci Nutr 2015.
68.
Wu F, Guclu H. Aflatoxin regulations in a network of global maize trade. PLoS ONE. 2012;7(9):e45151.PubMedPubMedCentralCrossRef
69.
Wu F, Stacy SL, Kensler TW. Global risk assessment of aflatoxins in maize and peanuts: are regulatory standards adequately protective? Toxicol Sci 2013;135(1):251–9.
70.
El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4(3):369–80.PubMedCrossRef
71.
Tatsch E, Carvalho JA, Hausen BS, Bollick YS, Torbitz VD, Duarte T, et al. Oxidative DNA damage is associated with inflammatory response, insulin resistance and microvascular complications in type 2 diabetes. Mutat Res. 2015;782:17–22.PubMedCrossRef
72.
Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes. 2010;59(1):249–55.PubMedCrossRef
73.
Chen J, Han Y, Xu C, Xiao T, Wang B. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies. Eur J Cancer Prev. 2015;24(2):89–99.PubMedCrossRef
74.
White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831–44.PubMedPubMedCentralCrossRef
75.
Chen HH, Lin MC, Muo CH, Yeh SY, Sung FC, Kao CH. Combination therapy of metformin and statin may decrease hepatocellular carcinoma among diabetic patients in Asia. Medicine (Baltimore). 2015;94(24):e1013.CrossRef
76.
Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013;62(4):606–15.PubMedCrossRef
77.
Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010;30(5):750–8.PubMedCrossRef
78.
Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010;116(8):1938–46.PubMedPubMedCentralCrossRef
79.
Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, et al. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res. 2013;19(19):5372–80.PubMedCrossRef
80.
Li J, Hernanda PY, Bramer WM, Peppelenbosch MP, van LJ, Pan Q. Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One 2015;10(6):e0127967.
81.
Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108(6):881–91.PubMedCrossRef
82.
Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell. 2014;26(3):331–43.PubMedPubMedCentralCrossRef
83.
Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97–101.PubMedCrossRef
84.
Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97(7):1005–8.PubMedPubMedCentral
85.
Schlesinger S, Aleksandrova K, Pischon T, Fedirko V, Jenab M, Trepo E, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer. 2013;132(3):645–57.PubMedCrossRef
86.
Woodford RM, Burton PR, O’Brien PE, Laurie C, Brown WA. Laparoscopic adjustable gastric banding in patients with unexpected cirrhosis: safety and outcomes. Obes Surg. 2015;25(10):1858–62.PubMedCrossRef
87.
Nobili V, Alisi A, Grimaldi C, Liccardo D, Francalanci P, Monti L et al. Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity? Pediatr Obes 2014;9(5):e99–e102.
88.
Berentzen TL, Gamborg M, Holst C, Sorensen TI, Baker JL. Body mass index in childhood and adult risk of primary liver cancer. J Hepatol. 2014;60(2):325–30.PubMedCrossRef
89.
Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85.PubMedCrossRef
90.
Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015.
91.
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31.PubMedCrossRef
92.
Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17(11):863–9.PubMedCrossRef
93.
Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl. 2012;18(1):29–37.PubMedCrossRef
94.
Wattacheril J, Chalasani N. Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition? Hepatology 2012;56(4):1580–4.
95.
Groopman JD, Zhu JQ, Donahue PR, Pikul A, Zhang LS, Chen JS, et al. Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region People’s Republic of China. Cancer Res. 1992;52(1):45–52.PubMed
96.
Ashtari S, Pourhoseingholi MA, Zali MR. Non-alcohol fatty liver disease in Asia: prevention and planning. World J Hepatol. 2015;7(13):1788–96.PubMedPubMedCentralCrossRef
97.
Meyer J, Rohrmann S, Bopp M, Faeh D. Impact of smoking and excess body weight on overall and site-specific cancer mortality risk. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1516–22.PubMedCrossRef
98.
Chuang SC, Lee YC, Hashibe M, Dai M, Zheng T, Boffetta P. Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19(5):1261–8.PubMedPubMedCentralCrossRef
99.
Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst. 2011;103(22):1686–95.PubMedPubMedCentralCrossRef
100.
Fan JH, Wang JB, Jiang Y, Xiang W, Liang H, Wei WQ, et al. Attributable causes of liver cancer mortality and incidence in china. Asian Pac J Cancer Prev. 2013;14(12):7251–6.PubMedCrossRef
101.
Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007;47(4):506–13.PubMedCrossRef
102.
McGlynn KA, Sahasrabuddhe VV, Campbell PT, Graubard BI, Chen J, Schwartz LM, et al. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project. Br J Cancer. 2015;112(7):1266–72.PubMedPubMedCentralCrossRef
103.
Yu MW, Chang HC, Chang SC, Liaw YF, Lin SM, Liu CJ, et al. Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology. 2003;38(6):1393–400.PubMed
104.
Bravi F, Bosetti C, Tavani A, Gallus S, La VC. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol. 2013;11(11):1413–21.PubMedCrossRef
105.
Johnson S, Koh WP, Wang R, Govindarajan S, Yu MC, Yuan JM. Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Cancer Causes Control. 2011;22(3):503–10.PubMedPubMedCentralCrossRef
106.
Bamia C, Lagiou P, Jenab M, Trichopoulou A, Fedirko V, Aleksandrova K, et al. Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer. 2015;136(8):1899–908.PubMedCrossRef
107.
Petrick JL, Freedman ND, Graubard BI, Sahasrabuddhe VV, Lai GY, Alavanja MC, et al. Coffee consumption and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by sex: the Liver Cancer Pooling Project. Cancer Epidemiol Biomarkers Prev. 2015;24(9):1398–406.PubMedCrossRef
108.
Aleksandrova K, Bamia C, Drogan D, Lagiou P, Trichopoulou A, Jenab M et al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2015.
109.
Torres DM, Harrison SA. Is it time to write a prescription for coffee? Coffee and liver disease. Gastroenterology. 2013;144(4):670–2.PubMedCrossRef
110.
Yu F, Jin Z, Jiang H, Xiang C, Tang J, Li T, et al. Tea consumption and the risk of five major cancers: a dose-response meta-analysis of prospective studies. BMC Cancer. 2014;14:197.PubMedPubMedCentralCrossRef
111.
Zhang YF, Xu Q, Lu J, Wang P, Zhang HW, Zhou L, et al. Tea consumption and the incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Eur J Cancer Prev. 2015;24(4):353–62.PubMedCrossRef
112.
Huang X, Kojima-Yuasa A, Xu S, Norikura T, Kennedy DO, Hasuma T, et al. Green tea extract enhances the selective cytotoxic activity of Zizyphus jujuba extracts in HepG2 cells. Am J Chin Med. 2008;36(4):729–44.PubMedCrossRef
113.
Huang YQ, Lu X, Min H, Wu QQ, Shi XT, Bian KQ et al. Green tea and liver cancer risk: a meta-analysis of prospective cohort studies in Asian populations. Nutrition 2015.
114.
Yang Y, Zhang D, Feng N, Chen G, Liu J, Chen G, et al. Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis. Gastroenterology. 2014;147(5):1031–42.PubMedCrossRef
115.
Luo J, Yang Y, Liu J, Lu K, Tang Z, Liu P, et al. Systematic review with meta-analysis: meat consumption and the risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2014;39(9):913–22.PubMedCrossRef
116.
Freedman ND, Cross AJ, McGlynn KA, Abnet CC, Park Y, Hollenbeck AR, et al. Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort. J Natl Cancer Inst. 2010;102(17):1354–65.PubMedPubMedCentralCrossRef
117.
Duarte-Salles T, Fedirko V, Stepien M, Aleksandrova K, Bamia C, Lagiou P, et al. Dietary fat, fat subtypes and hepatocellular carcinoma in a large European cohort. Int J Cancer. 2015;137(11):2715–28.PubMedCrossRef
118.
Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazu T, Yamaji T, et al. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology. 2012;142(7):1468–75.PubMedCrossRef
119.
Sharp GB, Lagarde F, Mizuno T, Sauvaget C, Fukuhara T, Allen N, et al. Relationship of hepatocellular carcinoma to soya food consumption: a cohort-based, case-control study in Japan. Int J Cancer. 2005;115(2):290–5.PubMedCrossRef
120.
Iso H, Kubota Y. Nutrition and disease in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC). Asian Pac J Cancer Prev. 2007;8(Suppl):35–80.PubMed
121.
Kurahashi N, Inoue M, Iwasaki M, Tanaka Y, Mizokami M, Tsugane S. Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women. Int J Cancer. 2009;124(7):1644–9.PubMedCrossRef
122.
Zhang W, Shu XO, Li H, Yang G, Cai H, Ji BT, et al. Vitamin intake and liver cancer risk: a report from two cohort studies in China. J Natl Cancer Inst. 2012;104(15):1173–81.PubMedCrossRef